Barbara Dalton

Vice President Pfizer Venture Investments at Pfizer, Inc.

Barbara Dalton

Barbara Dalton

Vice President Pfizer Venture Investments at Pfizer, Inc.

Overview
Career Highlights

SR One Ltd.

RelSci Relationships

3582

Number of Boards

30

Birthday

1953

Age

66

Relationships
RelSci Relationships are individuals Barbara Dalton likely has professional access to. A relationship does not necessarily indicate a personal connection.

General Partner at NEA Management Co. LLC

Relationship likelihood: Strong

Co-Founder at Alexandria Real Estate Equities, Inc.

Relationship likelihood: Strong

Co-Founder at Cydan II, Inc.

Relationship likelihood: Strong

Founder at Imara, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Lundbeckfonden Ventures

Relationship likelihood: Strong

Partner at NEA Management Co. LLC

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Morphic Holding, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Rodeo Therapeutics Corp.

Relationship likelihood: Strong

Vice President-Venture Investments at Johnson & Johnson Innovation JJDC, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Vtesse, Inc.

Relationship likelihood: Strong

Paths to Barbara Dalton
Potential Connections via
Relationship Science
You
Barbara Dalton
Vice President Pfizer Venture Investments at Pfizer, Inc.
Education
PhD in Microbiology & Immunology

Drexel University College of Medicine excels and innovates in education, research, and delivery of compassionate care in their culture of diversity, spirited inquiry, collaboration, and opportunity. Drexel University College of Medicine's strengths will be synergy and integration in the areas of biomedical research and education, technology, and clinical care. They build on their strong foundation of outstanding medical research, education, and compassionate care of our patients, bolstered by an exceptional, dedicated and diverse faculty, professional staff, and student body.

Career History
General Partner
2000 - 2007

Euclid SR focuses on investments in companies involved in the convergence of the life sciences and information technology sectors

Research Scientist in Immunology
Prior

In 1830 John K. Smith opened its first pharmacy in Philadelphia. In 1865 Mahlon Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891 it merged with French, Richard and Company. It changed its name to Smith Kline & French Laboratories in 1929 as it focused more on research. Years later Smith Kline & French Laboratories opened a new laboratory in Philadelphia; it then bought Norden Laboratories, a business doing research into animal health. Smith Kline & French Laboratories bought Recherche et Industrie Thérapeutiques (Belgium) in 1963 to focus on vaccines. The company started to expand globally, buying seven laboratories in Canada and the US in 1969. In 1982 it bought Allergan, a manufacturer of eye and skincare products. The company merged with Beckman Inc. later that year and changed its name to SmithKline Beckman

President
1993 - 2003

SR One focuses on investments in early-stage healthcare companies. The firm invests globally with a focus on North America and Europe. They invest at all stages of a company's development. SR One targets companies involved in drug discovery, drug development and tools that facilitate the discovery and development of new drugs. They are interested in companies with products that are in preclinical development through clinical proof-of-concept. SR One looks for investments that provide attractive financial returns and significant strategic value. The firm leads investments and works with other financial or strategic investors to syndicate deals. They are active investors and typically take board of directors or board observer seats. SR One is structured as an evergreen fund. They place approximately $25 million to $50 million each year, including follow-on investments in their portfolio companies. SR One invests between $500,000 and $5 million in each round of financing.

Boards & Committees
Member, Board of Directors
2018 - Current

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

Director
2017 - Current

Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA.

Director
2016 - Current

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Chairman, Health Care Sector Group
Current

The Partnership Fund for New York City was founded by Henry R. Kravis and capitalized by leaders of global business and finance. Established in 1996, the Fund operates as the economic development extension of Partnership NYC, the leading voice for New York’s business community. Each of our sixty-seven initial investors contributed $1 million to capitalize the fund for the benefit of New York City, and without expectation of financial return. To date, the Partnership Fund has invested in over 100 exemplary projects that have made and continue to make meaningful impact in local economic growth.

Member, Dean's Advisory Board
Current
Political Donations
$2,500
2016
$2,500
2014
$2,500
2013
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Barbara Dalton. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Barbara Dalton's profile does not indicate a business or promotional relationship of any kind between RelSci and Barbara Dalton.